MONECO Advisors LLC Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

MONECO Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 60,098 shares of the company’s stock after selling 418 shares during the period. Johnson & Johnson makes up 0.9% of MONECO Advisors LLC’s investment portfolio, making the stock its 25th biggest holding. MONECO Advisors LLC’s holdings in Johnson & Johnson were worth $8,691,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Knuff & Co LLC increased its position in Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after purchasing an additional 64 shares during the period. Vertex Planning Partners LLC increased its position in Johnson & Johnson by 1.3% during the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after purchasing an additional 65 shares during the period. Werba Rubin Papier Wealth Management increased its position in Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after purchasing an additional 66 shares during the period. Corepath Wealth Partners LLC increased its position in Johnson & Johnson by 3.7% during the 4th quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock worth $287,000 after purchasing an additional 70 shares during the period. Finally, Lifestyle Asset Management Inc. increased its position in Johnson & Johnson by 4.7% during the 4th quarter. Lifestyle Asset Management Inc. now owns 1,560 shares of the company’s stock worth $226,000 after purchasing an additional 70 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $166.13 on Wednesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock’s 50 day moving average price is $149.72 and its 200 day moving average price is $155.92. The firm has a market cap of $399.98 billion, a P/E ratio of 24.98, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the company posted $2.29 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Bank of America dropped their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Guggenheim upped their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.